Dyronib 70 Tablets (Dasatinib Tablets 70 mg)

Dyronib 70 Tablets is a branded oncology oral formulation containing dasatinib, a tyrosine kinase inhibitor used in regulated cancer treatment settings. Developed for professional pharmaceutical distribution, Dyronib 70 Tablets are supplied through licensed and compliant supply channels. AmeriDrugs offers this product strictly for export to authorized importers, distributors, hospitals, and pharmacies operating within regulated oncology and pharmaceutical markets.

Active Ingredient (API + Strength)

• Active Pharmaceutical Ingredient: Dasatinib

• Strength: 70 mg per tablet

• Dosage Form: Film-coated tablet

Therapeutic Use (Informational, Non-Advisory)
Dasatinib is a tyrosine kinase inhibitor utilized within approved oncology treatment protocols for specific hematological malignancies, including certain forms of leukemia, as determined by regulatory authorities. Dyronib 70 Tablets are supplied for use in accordance with locally approved clinical guidelines and prescribing information. This content is provided strictly for product identification and regulatory clarity and does not constitute medical advice or treatment recommendations.

Dosage Form & Route of Administration

• Dosage Form: Oral solid dosage (tablet)

• Route of Administration: Oral

• Prescription Status: Prescription-only medicine

• Intended for dispensing through regulated pharmaceutical and healthcare channels

Quality & Manufacturing Standards
Dyronib 70 Tablets are manufactured in compliance with current Good Manufacturing Practices (GMP) and applicable pharmacopeial standards. Production includes validated quality systems to ensure tablet uniformity, stability, and batch consistency. Each batch undergoes quality control testing aligned with international regulatory and export requirements.

Packaging Information (Export-Oriented)

• Primary Packaging: Blister strips

• Pack Size: 60 tablets per box

• Secondary Packaging: Printed carton with regulatory-compliant labeling

• Packaging suitable for international pharmaceutical logistics and oncology supply chains

Target Buyers

• Licensed pharmaceutical importers and distributors

• Oncology hospitals and specialty treatment centers

• Retail and wholesale pharmacies operating under prescription regulations

• Government and private healthcare procurement agencies

• International distributors specializing in oncology oral formulations

Regulatory & Compliance Note
Dyronib 70 Tablets is a prescription-only oncology medicine intended for regulated pharmaceutical distribution. Not for direct consumer self-use. Supply is subject to import authorization, local drug regulatory approvals, and applicable healthcare compliance requirements in the destination country. AmeriDrugs adheres to global export compliance standards and supports required regulatory documentation for international markets.